novocure Optune - What Studies Have Been Conducted with Optune?

12
7 What Studies Have Been Conducted with Optune
®
?
A clinical study tested Optune against the best standard of care chemotherapy (cancer drugs). The study included 237
subjects with recurrent GBM (120 Optune subjects and 117 cancer drugs subjects).
Subjects who used Optune lived a similar amount of time compared to subjects who were taking cancer drugs. Optune
subjects and cancer drugs subjects lived for an average of 6.4 months after treatment was started. In addition, the same
portion of subjects who used Optune or cancer drugs were alive one year after starting treatment. That is, 22 out of
every 100 subjects were alive at one year when using Optune or cancer drugs. Finally, when subjects used Optune, the
tumor shrank to at least half of its original size in 14 out of 100 (14%) Optune subjects compared to 7 out of 73 (10%)
cancer drugs subjects. Optune was similar to cancer drugs in other measures of treating GBM. Quality of life was better
in Optune subjects compared to cancer drugs subjects.
The number of subjects with digestive problems, blood problems, or infections was three times lower in the Optune
group than in the cancer drugs group. That is, 17 out of 91 subjects on cancer drugs had blood problems compared to
5 out of 116 subjects using Optune. 27 out of 91 subjects on cancer drugs had digestive problems compared to 9 out of
116 subjects using Optune. 11 out of 91 subjects on cancer drugs had infections compared to 5 out of 116 subjects using
Optune.
18 out of 116 Optune subjects had mild or moderate skin reaction under the transducer arrays (red rash, small sores or
blisters). This was expected. None of these cases of skin irritation caused damage to the skin that could not be fixed.
The reaction went away after being treated with steroid cream and moving the transducer arrays. In all cases, the rash
went away after stopping treatment. One subject had a larger open sore under his transducer arrays, which healed after
moving the transducer arrays to another place.
The clinical study found that Optune was similar in eectiveness to cancer drugs in treating recurrent GBM. Optune
subjects as a group had a better quality of life without many of the side eects of cancer drugs.
What Studies Have Been Conducted with Optune?\\DC - 099263/000001 - 12620961 v1